A Phase 1 study of the anti-tissue factor antibody-drug conjugate XB002 in patients with advanced solid tumors (JEWEL-101): initial results from the dose-escalation stage. (October 2022) - Ulahannan, S.; Johnson, M.L.; Park, H.; Vandross, A.; Uttamsingh, S.; Li, J.; Syed, M.; Tolcher, A.